Development of Anti-bodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis.
Background: Rheumatoid arthritis is a common chronic and destructive autoimmune arthropathy .Treatment with infliximab gives great improvement to a large numbers of patients with RA ,however, in some patients after prolonged treatment infliximab can induce anti-infliximab antibodies formation and result to loss of infliximab efficacy and active persistent disease.
Objective: to investigate the frequency of anti-infliximab antibodies in Iraqi patients with rheumatoid arthritis.
Patients and methods: fifty Iraqi RA patients(36 females and 14 males) compared with 50 control( 25 healthy control and 25 case control (patients with RA on other treatment) ) were included in this study from begging of March 2014 till end of September 2014.All patients were diagnosed by full history, complete clinical examination and laboratory test. Anti-infliximab antibodies were meatured using enzymelinked immunosorbent assay in serum of Iraqi patients with RA treated with infliximab more than 3 months
Results: Antibodies to infliximab were detected in 35(70%) Iraqi RA patients , while the patients without detectable antibodies against infliximab were 15(30%),also there were no anti-infliximab antibodies in the control groups.
Conclusion: In this study, nearly three quarter of the Iraqi RA patients treated with infliximab developed anti-infliximab antibodies.
For all articles published in Journal of the Faculty of Medicine Baghdad, copyright is retained by the authors. Articles are licensed under an open access Creative Commons CC BY NC 4.0 license, meaning that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. These conditions allow for maximum use and exposure of the work, while ensuring that the authors receive proper rights.